+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Asia-Pacific Diagnostic Biomarker Market 2019-2025

  • PDF Icon

    Report

  • January 2020
  • Region: Asia Pacific
  • Orion Market Research Private Limited
  • ID: 4991530
UP TO OFF until Dec 31st 2022
Asia-Pacific Diagnostic Biomarker Market Size, Share & Trends Analysis Report by Diagnostic Technique (ELISA, Colorimetric Assay, Liquid Chromatography-Mass Spectrometry, Particle-Enhanced Turbidimetric Immunoassay, and Others), By Application (Oncology, Cardiology, Neurology, Nephrology, and Others), and Forecast 2019-2025.

The Asia-Pacific diagnostic biomarker market is estimated to grow significantly at a CAGR of around 14% during the forecast period. Asia-Pacific is both a strong and promising market for diagnostic biomarkers. This is particularly due to the strong population base, high prevalence of chronic diseases such as cancer and CVDs in Asian countries such as China, Japan, and India. China has a strong market for diagnostic biomarkers due to huge government investments in R&D and life science projects, the prevalence of chronic diseases such as cancer and the increasing adoption of personalized medicine. All these factors are contributing to the growth of the diagnostic biomarker market in China.

The Asia-Pacific diagnostic biomarker market is segmented on the basis of diagnostic technique and application. On the basis of the diagnostic technique, the market is segmented into ELISA, colorimetric assay, liquid chromatography-mass spectrometry, particle-enhanced turbidimetric immunoassay and other. Further, on the basis of application, the market is segmented into oncology, cardiology, neurology, nephrology, and others. There is a huge scope for the market in the oncology segment due to the increasing prevalence of cancer. A large number of researches are going on finding a diagnostic biomarker for various types of cancer so that early detection can be done.

Some of the major players in the Asia-Pacific diagnostic biomarker market include Abbott Laboratories, Inc., Thermo Fisher Scientific, inc., Astellas Pharmaceutical Inc., F. Hoffmann-La Roche Ltd., Evotec AG, Becton Dickinson and Co., Qiagen NV, Novartis AG, and others. These companies are launching innovative products in the market, in order to meet the increasing demand for an effective diagnostic biomarker for cancer and cardiovascular diseases. Furthermore, the market players are adopting various strategies, in order to sustain in the competitive market, which includes partnership and collaboration, and investments.

Research Methodology

The market study of the Asia-Pacific diagnostic biomarker market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors.

Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include
  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report is intended for healthcare companies, research institutes, hospitals, pharmaceutical, and biotechnology companies, potential investors and venture capitalists, government organizations, and other market participants for the overall market and competitive analysis. The report provides an in-depth analysis of the market size and future market opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Asia-Pacific Diagnostic Biomarker Market Research and Analysis by Diagnostic Technique
2. Asia-Pacific Diagnostic Biomarker Market Research and Analysis by Application

The Report Covers
  • Comprehensive research methodology of the Asia-Pacific Diagnostic Biomarker Market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the Asia-Pacific Diagnostic Biomarker Market.
  • Insights about market determinants which are stimulating the Asia-Pacific Diagnostic Biomarker Market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. Asia-Pacific Diagnostic Biomarker Market by Diagnostic Technique
5.1.1. ELISA
5.1.2. Colorimetric Assay
5.1.3. Liquid Chromatography-Mass Spectrometry
5.1.4. Particle-Enhanced Turbidimetric Immunoassay
5.1.5. Others
5.2. Asia-Pacific Diagnostic Biomarker Market by Application
5.2.1. Oncology
5.2.2. Cardiology
5.2.3. Neurology
5.2.4. Nephrology
5.2.5. Others
6. Regional Analysis
6.1. China
6.2. Japan
6.3. India
6.4. Rest of Asia-Pacific
7. Company Profiles
7.1. Abbott Laboratories Inc.
7.2. Agilent Technologies, Inc.
7.3. Astellas Pharma Inc.
7.4. Bayer AG
7.5. Beckman Coulter Inc.
7.6. Becton, Dickson and Co.
7.7. BioMérieux S.A.
7.8. Bio-Rad Laboratories, Inc.
7.9. Evotec AG
7.10. F-Hoffman-La Roche Ltd.
7.11. Lucence Diagnostics Pte Ltd.
7.12. Novartis AG
7.13. Otsuka Pharmaceutical Co., Ltd.
7.14. Pfizer, Inc.
7.15. Qiagen N.V.
7.16. Shuwen Biotech Co., LTD
7.17. Thermo Fisher Scientific Inc.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Abbott Laboratories Inc.
  • Agilent Technologies, Inc.
  • Astellas Pharma Inc.
  • Bayer AG
  • Beckman Coulter Inc.
  • Becton, Dickson and Co.
  • BioMérieux S.A.
  • Bio-Rad Laboratories, Inc.
  • Evotec AG
  • F-Hoffman-La Roche Ltd.
  • Lucence Diagnostics Pte Ltd.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer, Inc.
  • Qiagen N.V.
  • Shuwen Biotech Co., LTD
  • Thermo Fisher Scientific Inc.